PD-L1 CPS est une cote continue IHC utilisée comme seuil d'admissibilité pour les ICI contenant des r...

Vue déterministe de l'entité source de la LJAM. L'autorité clinique demeure avec les ID de la source cités et l'état d'approbation de l ́examinateur.

ID	`BMA-PDL1-CPS-GASTRIC`
Type	Pertinence thérapeutique
État	reviewed 2026-05-07 \| actionability review required
Maladies	`DIS-GASTRIC`
Sources	`SRC-CHECKMATE-649-JANJIGIAN-2022` `SRC-ESMO-GASTRIC-2024` `SRC-NCCN-GASTRIC-2025`

Faits relatifs à l ' action en justice

Biomarqueur	`BIO-PDL1-CPS`
Maladie	`DIS-GASTRIC`
Niveau ESCAT	IA
Combinaisons recommandées	nivolumab + fluoropyrimidine + platinum (CPS≥5, 1L per SRC-NCCN-GASTRIC-2025, SRC-ESMO-GASTRIC-2024), nivolumab + FOLFOX/XELOX (CPS≥1 broader population per SRC-CHECKMATE-649-JANJIGIAN-2022)
Résumé des faits	PD-L1 CPS is a continuous IHC score used as an eligibility threshold for ICI-containing regimens in metastatic gastric/GEJ adenocarcinoma. Thresholds vary by regimen: CPS ≥5 — nivolumab + fluoropyrimidine + platinum (CheckMate-649; mOS 14.4 vs 11.1 mo, HR 0.71 in CPS≥5 subgroup); CPS ≥1 — nivolumab + chemo as broader population (CM-649); CPS ≥1 — pembrolizumab + trastuzumab + chemo for HER2+ disease (KEYNOTE-811, covered separately in BMA-HER2-AMP-GASTRIC). Per NCCN and ESMO 2024, PD-L1 CPS testing by IHC 22C3 pharmDx is mandatory prior to 1L treatment selection. Threshold-gated indication selection is performed by the algorithm layer (IND-GASTRIC-METASTATIC-1L-PDL1-CHEMO-ICI); this BMA entry surfaces ESCAT tier context for tumor-board discussion only.

Notes

Variant_qualifier is null (gene-level) — CPS is a continuous score; specific threshold gating (CPS≥5 vs ≥1) is enforced by the indication layer, not this BMA cell. This entry exists to prevent the render layer from showing "Not in KB" for a well-defined, FDA-approved biomarker. KEYNOTE-811 evidence is attributable to BMA-HER2-AMP-GASTRIC to avoid overlap.

Utilisé par

No reverse references found in the YAML corpus.